Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

PURPOSE: To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) –positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second object...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellis, Matthew J., Suman, Vera J., Hoog, Jeremy, Goncalves, Rodrigo, Sanati, Souzan, Creighton, Chad J., DeSchryver, Katherine, Crouch, Erika, Brink, Amy, Watson, Mark, Luo, Jingqin, Tao, Yu, Barnes, Michael, Dowsett, Mitchell, Budd, G. Thomas, Winer, Eric, Silverman, Paula, Esserman, Laura, Carey, Lisa, Ma, Cynthia X., Unzeitig, Gary, Pluard, Timothy, Whitworth, Pat, Babiera, Gildy, Guenther, J. Michael, Dayao, Zoneddy, Ota, David, Leitch, Marilyn, Olson, John A., Allred, D. Craig, Hunt, Kelly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455353/
https://www.ncbi.nlm.nih.gov/pubmed/28045625
http://dx.doi.org/10.1200/JCO.2016.69.4406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455353/
https://www.ncbi.nlm.nih.gov/pubmed/28045625
http://dx.doi.org/10.1200/JCO.2016.69.4406

Ejemplares similares